investors & media
NASDAQ: (common stock)
Data Provided by Refinitiv. Minimum 15 minutes delayed.
European Medicines Agency will evaluate eli-cel MAA under accelerated assessment CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 2, 2020-- bluebird bio, Inc . (Nasdaq: BLUE) today announced that the European Medicines Agency (EMA) accepted the company’s marketing authorization application (MAA) for itsRead more
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 28, 2020-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Jefferies Cell Therapy Virtual Summit, Tuesday, October 6 , at 2:00 p.m. ET . To access the live webcast of bluebird bio’s presentation,Read more
EMA’s PRIME program designed to optimize development and expedite evaluation of innovative medicines for patients with high unmet need CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 23, 2020-- bluebird bio, Inc. (Nasdaq: BLUE) announced today that its investigational treatment for sickle cell diseaseRead more